2022 Séptémber: Numutkeun kana panilitian anu diterbitkeun dina Journal of Clinical Investigation, insinyur di Universitas Houston (UH) tiasa mendakan mékanisme pikeun ngaidentipikasi pasien limfoma anu paling dipikaresep ngabales terapi sél T-réséptor antigen chimeric (CAR).
Physicians can expedite treatment and maybe save more lives if they are aware of which lymphoma patients react to CAR T-cell therapy. On the other hand, sharing light on people who react poorly and experience serious side effects can open up more possibilities for alternative treatments.
Panaliti mendakan sambungan khusus antara protéin sél T CD2 sareng reséptor kanker CD58 dina panyelidikanana.
In the tumours of lymphoma patients who benefit more from Terapi sél T-mobil, the CD2 ligand CD58 is expressed at higher levels, according to study author Navin Varadarajan, PhD, MD Anderson professor of chemical and biomolecular engineering.
Protéin CD2 sél AT kabeungkeut ku CD58. Nalika CD58 ngaktifkeun CD2, protéinna robih janten molekul anu tiasa ngaleungitkeun sél kanker nalika kontak.
According to certain recent studies, cancer can be treated by using the patient’s own biological system. One particular technique, called Terapi sél T-mobil, modifies T cells in the lab so that they will fight cancer cells once they have returned to the body. The consequences of this life-saving procedure could linger for ten years or longer.
Dina raraga ngalaksanakeun panalungtikan leuwih teleb kana sambungan antara CD58 jeung CD2, Varadarajan gawé bareng jeung tim panalungtikan ti Universitas Texas MD Anderson Kangker Center.
Varadarajan gawé bareng sareng Sattva Neelapu (MD Anderson) pikeun ngawarnaan tumor pasien sateuacan perlakuan CAR T sareng mariksa ekspresi sél nganggo téknik TIMING (Timelapse Imaging Microscopy In Nanowell Grids) anu dikembangkeun ku Varadarajan di lab na. Téknologi sél tunggal-throughput tinggi ieu tiasa meunteun kumaha sél mindahkeun, ngaktifkeun, maéhan, salamet, sareng berinteraksi.
The scientists discovered that tumours expressing higher amounts of the cancer receptor CD58 responded better to Terapi sél T-mobil based on the hundreds of interactions they saw between T cells and tumour cells using TIMING.
Varadarajan stated in the news announcement, “We found that CD2 on T cells is related with directional migration. Death and serial killing are accelerated by the interaction between CD2 on T cells and CD58 on lymphoma sél.
Varadarajan narékahan pikeun komersilkeun téknik TIMING. Anjeunna ko-ngadegkeun bisnis basis UH CellChorus. Pasén tiasa ngalebetkeun CellChorus sél targetna sacara individu; sél-sél ieu bakal ditalungtik nganggo tés TIMING; jasa ieu teu acan diaksés ka professional.
Dina siaran pers, Varadarajan nyarios, "Kami bagja pisan ngagaduhan Jambatan Téknologi salaku lokasi inkubator kami di Houston, gigireun fasilitas médis luhur bangsa, kalayan aksés unik kana pusat-pusat kadokteran anu hese ditiru di kalolobaan kota-kota sanés di nagara.
